Clinical Safety and Tolerability of New Specialized Food Product
The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. New sp...
Saved in:
Published in | Current developments in nutrition Vol. 6; no. Supplement_1; p. 319 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Inc
01.06.2022
Oxford University Press |
Subjects | |
Online Access | Get full text |
ISSN | 2475-2991 2475-2991 |
DOI | 10.1093/cdn/nzac053.060 |
Cover
Abstract | The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis.
New specialized food product (SPP2) was developed based on literature data on the efficacy of active biological compounds on pathogenesis of NASH. It contains: protein, fat, ω-3 PUFAs, carbohydrates, soluble fibre, Coenzime Q10, L-carnitine, α-lipoic acid, vitamins (A, B1, B2, B6, PP, B12, D3, C, K), phospholipids. The test batch of the product passed laboratory control for biological and toxicological safety. The study was approved by LEC and registered (NCT04308980). Patients with NASH (per EASL), were invited to participate and were randomized to receive iso-caloric diet alone (ICD) or iso-caloric diet and SPP2 (SPP2). Energy value of the diet was amended by calorie content of SPP2. The patients were advised to follow usual physical activity and report any adverse events (AE) occurred during the study. Organoleptic assessment with the use of 5-point Likert scale and repeated blood tests on chemistry and hematology were performed at baseline (BL) and after 14 days (EOT) of treatment. Non-parametric statistics was used for the analysis
One subject was lost to follow-up in ICD group and one postponed the use of SPP2 due to the not related to safety reasons. The data of 25 subjects were available for the final analysis. The ICD (n = 8) and SPP2 (n = 17) groups did not differ by demographic and baseline characteristics. Adherence to diet was 88% in ICD and 92% in SPP2 groups, p = 0.7. Compliance with SPP was 97%. No serious adverse events occurred during the study. Organoleptic assessment of SPP2 initially: appearance (Mean ± SD) 3.9 ± 0.83 points; color 4.0 ± 0.5; aroma 3.6 ± 0.9; texture 3.7 ± 0.8; taste 3.9 ± 0.7; resulting in a mean score 3.9 ± 0.4 point at BL. No dissatisfaction revealed at EOT: the mean organoleptic score was 4.2 ± 0.7 points (P = 0.07). No laboratory AEs occurred.
New specialized food product “SPP2” in combination with iso-calorie diet is safe and well-tolerated by patients with NASH.
Ministry of Science and Higher Education of Russia, FGMF-2022–0005. |
---|---|
AbstractList | Objectives The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. Methods New specialized food product (SPP2) was developed based on literature data on the efficacy of active biological compounds on pathogenesis of NASH. It contains: protein, fat, ω-3 PUFAs, carbohydrates, soluble fibre, Coenzime Q10, L-carnitine, α-lipoic acid, vitamins (A, B1, B2, B6, PP, B12, D3, C, K), phospholipids. The test batch of the product passed laboratory control for biological and toxicological safety. The study was approved by LEC and registered (NCT04308980). Patients with NASH (per EASL), were invited to participate and were randomized to receive iso-caloric diet alone (ICD) or iso-caloric diet and SPP2 (SPP2). Energy value of the diet was amended by calorie content of SPP2. The patients were advised to follow usual physical activity and report any adverse events (AE) occurred during the study. Organoleptic assessment with the use of 5-point Likert scale and repeated blood tests on chemistry and hematology were performed at baseline (BL) and after 14 days (EOT) of treatment. Non-parametric statistics was used for the analysis Results One subject was lost to follow-up in ICD group and one postponed the use of SPP2 due to the not related to safety reasons. The data of 25 subjects were available for the final analysis. The ICD (n = 8) and SPP2 (n = 17) groups did not differ by demographic and baseline characteristics. Adherence to diet was 88% in ICD and 92% in SPP2 groups, p = 0.7. Compliance with SPP was 97%. No serious adverse events occurred during the study. Organoleptic assessment of SPP2 initially: appearance (Mean ± SD) 3.9 ± 0.83 points; color 4.0 ± 0.5; aroma 3.6 ± 0.9; texture 3.7 ± 0.8; taste 3.9 ± 0.7; resulting in a mean score 3.9 ± 0.4 point at BL. No dissatisfaction revealed at EOT: the mean organoleptic score was 4.2 ± 0.7 points (P = 0.07). No laboratory AEs occurred. Conclusions New specialized food product “SPP2” in combination with iso-calorie diet is safe and well-tolerated by patients with NASH. Funding Sources Ministry of Science and Higher Education of Russia, FGMF-2022–0005. The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. New specialized food product (SPP2) was developed based on literature data on the efficacy of active biological compounds on pathogenesis of NASH. It contains: protein, fat, ω-3 PUFAs, carbohydrates, soluble fibre, Coenzime Q10, L-carnitine, α-lipoic acid, vitamins (A, B1, B2, B6, PP, B12, D3, C, K), phospholipids. The test batch of the product passed laboratory control for biological and toxicological safety. The study was approved by LEC and registered (NCT04308980). Patients with NASH (per EASL), were invited to participate and were randomized to receive iso-caloric diet alone (ICD) or iso-caloric diet and SPP2 (SPP2). Energy value of the diet was amended by calorie content of SPP2. The patients were advised to follow usual physical activity and report any adverse events (AE) occurred during the study. Organoleptic assessment with the use of 5-point Likert scale and repeated blood tests on chemistry and hematology were performed at baseline (BL) and after 14 days (EOT) of treatment. Non-parametric statistics was used for the analysis One subject was lost to follow-up in ICD group and one postponed the use of SPP2 due to the not related to safety reasons. The data of 25 subjects were available for the final analysis. The ICD (n = 8) and SPP2 (n = 17) groups did not differ by demographic and baseline characteristics. Adherence to diet was 88% in ICD and 92% in SPP2 groups, p = 0.7. Compliance with SPP was 97%. No serious adverse events occurred during the study. Organoleptic assessment of SPP2 initially: appearance (Mean ± SD) 3.9 ± 0.83 points; color 4.0 ± 0.5; aroma 3.6 ± 0.9; texture 3.7 ± 0.8; taste 3.9 ± 0.7; resulting in a mean score 3.9 ± 0.4 point at BL. No dissatisfaction revealed at EOT: the mean organoleptic score was 4.2 ± 0.7 points (P = 0.07). No laboratory AEs occurred. New specialized food product “SPP2” in combination with iso-calorie diet is safe and well-tolerated by patients with NASH. Ministry of Science and Higher Education of Russia, FGMF-2022–0005. Abstract Objectives The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. Methods New specialized food product (SPP2) was developed based on literature data on the efficacy of active biological compounds on pathogenesis of NASH. It contains: protein, fat, ω-3 PUFAs, carbohydrates, soluble fibre, Coenzime Q10, L-carnitine, α-lipoic acid, vitamins (A, B1, B2, B6, PP, B12, D3, C, K), phospholipids. The test batch of the product passed laboratory control for biological and toxicological safety. The study was approved by LEC and registered (NCT04308980). Patients with NASH (per EASL), were invited to participate and were randomized to receive iso-caloric diet alone (ICD) or iso-caloric diet and SPP2 (SPP2). Energy value of the diet was amended by calorie content of SPP2. The patients were advised to follow usual physical activity and report any adverse events (AE) occurred during the study. Organoleptic assessment with the use of 5-point Likert scale and repeated blood tests on chemistry and hematology were performed at baseline (BL) and after 14 days (EOT) of treatment. Non-parametric statistics was used for the analysis Results One subject was lost to follow-up in ICD group and one postponed the use of SPP2 due to the not related to safety reasons. The data of 25 subjects were available for the final analysis. The ICD (n = 8) and SPP2 (n = 17) groups did not differ by demographic and baseline characteristics. Adherence to diet was 88% in ICD and 92% in SPP2 groups, p = 0.7. Compliance with SPP was 97%. No serious adverse events occurred during the study. Organoleptic assessment of SPP2 initially: appearance (Mean ± SD) 3.9 ± 0.83 points; color 4.0 ± 0.5; aroma 3.6 ± 0.9; texture 3.7 ± 0.8; taste 3.9 ± 0.7; resulting in a mean score 3.9 ± 0.4 point at BL. No dissatisfaction revealed at EOT: the mean organoleptic score was 4.2 ± 0.7 points (P = 0.07). No laboratory AEs occurred. Conclusions New specialized food product “SPP2” in combination with iso-calorie diet is safe and well-tolerated by patients with NASH. Funding Sources Ministry of Science and Higher Education of Russia, FGMF-2022–0005. |
Author | Isakov, Vasily Sasunova, Armida Morozov, Sergey |
Author_xml | – sequence: 1 givenname: Sergey surname: Morozov fullname: Morozov, Sergey organization: Federal Research Center of Nutrition and Biotechnology – sequence: 2 givenname: Armida surname: Sasunova fullname: Sasunova, Armida organization: Federal Research Center of Nutrition and Biotechnology – sequence: 3 givenname: Vasily surname: Isakov fullname: Isakov, Vasily organization: Federal Research Center of Nutrition and Biotechnology |
BookMark | eNqNkV1L5DAUhsOisH5d723BO2FmkpxpO7kRZdBVEBV0r8NpcrIbrUlNW2X89VvpgB8X4lVC8j4vJ0-22UaIgRj7JfhUcAUzY8MsvKDhOUx5wX-wLTkv84lUSmy82_9ke217xzkXSqmCqy12tKx98Abr7AYddasMg81uY00JK1_74SC67JKes5uGjMfav5DNTmO02XWKtjfdLtt0WLe0t1532J_Tk9vl2eTi6vf58vhiYqQq-cQ5KLHiuXQIVW6sUxaFQTcvqgUAXwgowEhAtbAA5TyXVSUXBFI4WUhwBDuMj719aHD1jHWtm-QfMK204PpVgh4k6LUEPUgYkMMRafrqgayh0CV8wyJ6_fEm-H_6b3zSSiiAXA4F--uCFB97ajt9F_sUhmdqEIXKhcqhHFKzMWVSbNtE7huDHYxE7JtvhNUYpsHuk6ekW-MpGLI-kem0jf4LtvzEmvV339PqS_I_f5i6UA |
ContentType | Journal Article |
Copyright | 2022 American Society for Nutrition. The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. 2022 The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2022 American Society for Nutrition. – notice: The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. 2022 – notice: The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 6I. AAFTH TOX AAYXX CITATION 3V. 7RV 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S NAPCQ PHGZM PHGZT PIMPY PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 5PM ADTOC UNPAY |
DOI | 10.1093/cdn/nzac053.060 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Oxford Journals Open Access Collection CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 3 dbid: BENPR name: ProQuest Central - New (Subscription) url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 2475-2991 |
EndPage | 319 |
ExternalDocumentID | 10.1093/cdn/nzac053.060 PMC9193352 10_1093_cdn_nzac053_060 S2475299123133385 |
GroupedDBID | .1- .FO 0R~ 7RV 7X7 8FI 8FJ AAFWJ AAHBH AALRI AAPXW AAVAP AAXUO AAYWO ABPTD ABUWG ABXVV ACGFS ACVFH ADBBV ADCNI ADVLN AEUPX AFJKZ AFKRA AFPKN AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMNDL AMRAJ AOIJS APXCP BAYMD BCNDV BENPR CCPQU EBS EJD EMOBN FDB FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR INH ITC KSI M~E NAPCQ O9- OK1 PHGZM PHGZT PIMPY PPXIY PUEGO RPM UKHRP Z5R 6I. AAFTH ABDBF AFCTW AFULF BTTYL OJZSN ROX TOX 0SF AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 5PM ADTOC UNPAY |
ID | FETCH-LOGICAL-c2970-ff37ab052fa3b5cdf9da1caf46b833081363c23a98d337452bb28e321f2623fe3 |
IEDL.DBID | 7X7 |
ISSN | 2475-2991 |
IngestDate | Mon Sep 15 10:01:21 EDT 2025 Tue Sep 30 17:06:26 EDT 2025 Fri Sep 19 20:53:59 EDT 2025 Wed Oct 01 01:49:16 EDT 2025 Wed Aug 28 03:17:35 EDT 2024 Fri Feb 23 02:36:31 EST 2024 Tue Aug 26 16:32:44 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com cc-by |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2970-ff37ab052fa3b5cdf9da1caf46b833081363c23a98d337452bb28e321f2623fe3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
OpenAccessLink | https://www.proquest.com/docview/3169519537?pq-origsite=%requestingapplication% |
PQID | 3169519537 |
PQPubID | 7121353 |
PageCount | 1 |
ParticipantIDs | unpaywall_primary_10_1093_cdn_nzac053_060 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9193352 proquest_journals_3169519537 crossref_primary_10_1093_cdn_nzac053_060 oup_primary_10_1093_cdn_nzac053_060 elsevier_sciencedirect_doi_10_1093_cdn_nzac053_060 elsevier_clinicalkey_doi_10_1093_cdn_nzac053_060 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20220601 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: 20220601 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford |
PublicationTitle | Current developments in nutrition |
PublicationYear | 2022 |
Publisher | Elsevier Inc Oxford University Press |
Publisher_xml | – name: Elsevier Inc – name: Oxford University Press |
SSID | ssj0001999609 |
Score | 2.187774 |
Snippet | The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to... Abstract Objectives The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of... Objectives The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study... |
SourceID | unpaywall pubmedcentral proquest crossref oup elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 319 |
SubjectTerms | Dietary Bioactive Components Food products |
SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEB_q9UFf1FrFq7UEFNGH_Uiym-y-eUiPUrAUegf1KeSTFs_do71D7v56k_04eoVaBJ83k81OZie_TGZ-AfgYXCApNY-Uy3WUWVxEErPc2zJ2WUqpLnSoRv5-xk6m2ellfrkDk74WRnZZ4fGmpMFUSafEaG5cwpLmussmdiZw4i0oCRR3oQA0qdZSe6OKU5bGvu0T2GXh2GkAu9Oz89GPcM9cxvPIe2Dcs_yUtHnDHcmHFqit-rcAQ-8nUT5dVnO5-i1nszsr1PgFLPtvaxNTfsbLhYr1-h7t4__--JfwvIO0aNT2sAc7tnoF-6PKb-d_rdAn1CSZNtH7ffja8ZDO0IV0drFCsjJoUs_sTcsXvkK1Q97xoou5DcH867U1aFzXBp231LSvYTo-nnw7ibpLHCJNSp5GzlEuVZoTJ6nKtXGlkVhLlzFVUOoBCWVUEyrLwlDKs5woRQpLCXbEIzNn6RsYVHVl3wKymd9tqdwQ5WgmLSsw15zLvFA4M5oVQ_jcz5yYt1wdoj1jp8JrUnQaEl5DQ0j7mRV9Cap3msKvIw-LkI1Ih05a1PF3oQ9-Lh8fzWFvVqJzIbeCYlYG6h_Kh8C3TG3TXaAG335SXV81FOGlx-UeWg_hy8YoHxvEwT-0fQfPSCgDaaJRhzBY3Cztew_OFuqo-9f-ABU2Ojc priority: 102 providerName: Unpaywall |
Title | Clinical Safety and Tolerability of New Specialized Food Product |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2475299123133385 https://dx.doi.org/10.1093/cdn/nzac053.060 https://www.proquest.com/docview/3169519537 https://pubmed.ncbi.nlm.nih.gov/PMC9193352 https://academic.oup.com/cdn/article-pdf/6/Supplement_1/319/44040997/nzac053.060.pdf |
UnpaywallVersion | publishedVersion |
Volume | 6 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2475-2991 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: DOA dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2475-2991 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: M~E dateStart: 20170101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2475-2991 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: RPM dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2475-2991 dateEnd: 20221231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: 7X7 dateStart: 20170101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central - New (Subscription) customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2475-2991 dateEnd: 20221231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: BENPR dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fb9MwELZge4AXxBiIwqgsgRA8hMZ2EidPrEOrJiRKBa1Uniz_1CYVp2ydUPfXc06cbkWwveQh0UXW3fn8-ez7DqE3IQTSSvNEuVwnmSVlIkmRgy8Tl6WM6VKHauQv4-Jkln2e5_OYcLuI1yq7mNgEalPrkCMfMFJUgQmF8Y_LX0noGhVOV2MLjftolwBUCV7N5_w6xxLQfFp1jD4VG2jjB_5KanC9D2lDS_nPxWir1i1Azr8vTD649Eu5_i0Xixur0egxehRhJB62dt9D96x_gvaHHrbQP9f4LW4udjYZ8310GLk_F_i7dHa1xtIbPK0X9rzl6F7j2mEIdjj2oj-7sgaP6trgSUsH-xTNRsfTTydJbJyQaFrxNHGOcanSnDrJVK6Nq4wkWrqsUCVjAAJYwTRlsioNYzzLqVK0tIwSRwENOcueoR1fe_scYZvBDkflhirHMmmLknDNucxLRTKji7KH3nUaFMuWH0O059pMgLJFVLYAZfdQ2mlYdGWfEKgExO7_i9CNSEQE7Up_u9BrMN_doznozCvitL0Q107WQ3zL5JvfBTru7S_-7LSh5a4ACwOc7aH3G-e4axAvbh_ES_SQhmqLJulzgHZW55f2FWCgleo3jt5Hu0fH48m3fpNJgOf06xzezcaT4Y8_MuANsA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VciiXCiiIbQu1xENwCBs_EicHBFVhtaUPIXUr7c34KSptk6Xdqkp_FL8RO48ti6A99RzZsma-jL8Zez4DvAohkOSaR8olOmIWZ5HEaeKxjB2LKdWZDt3IB4fp8Jh9HSfjJfjV9cKEa5VdTKwDtSl1qJH3KU7zoIRC-cfpzyi8GhVOV7snNBpY7Nnq0qds5x92P3v_viZk8GW0M4zaVwUiTXIeR85RLlWcECepSrRxuZFYS8dSlfnkPsM0pZpQmWeGUs4SohTJLCXYEU8VnKV-3ntwn9GYBa1-PubXNZ2QPcR5pyCU0742Rb-4ktpD_X1cy2D-c_Nb6K0LFPfvC5orF8VUVpdyMvlj9xs8hNWWtqLtBmePYMkWj2Ftu_Ap-2mF3qD6ImldoV-DT63W6AQdSWdnFZKFQaNyYs8aTfAKlQ754IqOpjYU7E-urEGDsjToWyM_-wSO78SkT2G5KAv7DJBlPqNSiSHKUSZtmmGuOZdJpjAzOs168LazoJg2ehyiOUenwhtbtMYW3tg9iDsLi67N1AdG4feK_w8h8yEtA2mYxc2DXnr33b6azc69og0T5-Ia1D3gCy6fTxfkvxe_FCc_ahnw3HNvT5978G4OjtsWsX7zIrZgZTg62Bf7u4d7G_CAhE6PuuC0Ccuzswv73POvmXpRgx7B97v-y34DqTlEtw |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEB_q9UFf1FrFq7UEFNGH_Uiym-y-eUiPUrAUegf1KeSTFs_do71D7v56k_04eoVaBJ83k81OZie_TGZ-AfgYXCApNY-Uy3WUWVxEErPc2zJ2WUqpLnSoRv5-xk6m2ellfrkDk74WRnZZ4fGmpMFUSafEaG5cwpLmussmdiZw4i0oCRR3oQA0qdZSe6OKU5bGvu0T2GXh2GkAu9Oz89GPcM9cxvPIe2Dcs_yUtHnDHcmHFqit-rcAQ-8nUT5dVnO5-i1nszsr1PgFLPtvaxNTfsbLhYr1-h7t4__--JfwvIO0aNT2sAc7tnoF-6PKb-d_rdAn1CSZNtH7ffja8ZDO0IV0drFCsjJoUs_sTcsXvkK1Q97xoou5DcH867U1aFzXBp231LSvYTo-nnw7ibpLHCJNSp5GzlEuVZoTJ6nKtXGlkVhLlzFVUOoBCWVUEyrLwlDKs5woRQpLCXbEIzNn6RsYVHVl3wKymd9tqdwQ5WgmLSsw15zLvFA4M5oVQ_jcz5yYt1wdoj1jp8JrUnQaEl5DQ0j7mRV9Cap3msKvIw-LkI1Ih05a1PF3oQ9-Lh8fzWFvVqJzIbeCYlYG6h_Kh8C3TG3TXaAG335SXV81FOGlx-UeWg_hy8YoHxvEwT-0fQfPSCgDaaJRhzBY3Cztew_OFuqo-9f-ABU2Ojc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Safety+and+Tolerability+of+New+Specialized+Food+Product&rft.jtitle=Current+developments+in+nutrition&rft.au=Morozov%2C+Sergey&rft.au=Sasunova%2C+Armida&rft.au=Isakov%2C+Vasily&rft.date=2022-06-01&rft.pub=Elsevier+Inc&rft.issn=2475-2991&rft.eissn=2475-2991&rft.volume=6&rft.spage=319&rft.epage=319&rft_id=info:doi/10.1093%2Fcdn%2Fnzac053.060&rft.externalDocID=S2475299123133385 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2475-2991&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2475-2991&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2475-2991&client=summon |